{
    "items": [
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1116923\" title=\"A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial\" class=\"state-synced\">A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1138303\" title=\"A RETROSPECTIVE ANALYSIS OF RESPIRATORY INFECTIONS AND NASOPHARYNGITIS RATES IN TRIALS OF ANTI-IL-17A THERAPIES\" class=\"state-synced\">A RETROSPECTIVE ANALYSIS OF RESPIRATORY INFECTIONS AND NASOPHARYNGITIS RATES IN TRIALS OF ANTI-IL-17A THERAPIES</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1137889\" title=\"NEUTROPHIL SUB-TYPES ACROSS LUNG DISEASES\" class=\"state-synced\">NEUTROPHIL SUB-TYPES ACROSS LUNG DISEASES</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1138298\" title=\"RELATIONSHIP BETWEEN INFLAMMATORY TYPE OF OBSTRUCTIVE AIRWAYS DISEASE AND LUNG FUNCTION IN A COHORT OF THE OXFORD SPECIAL AIRWAYS CLINIC\" class=\"state-synced\">RELATIONSHIP BETWEEN INFLAMMATORY TYPE OF OBSTRUCTIVE AIRWAYS DISEASE AND LUNG FUNCTION IN A COHORT OF THE OXFORD SPECIAL AIRWAYS CLINIC</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1138299\" title=\"EXHALED NITRIC OXIDE AND BLOOD EOSINOPHIL COUNT IN PREDICTING SPUTUM INFLAMMATORY TYPE IN A HETEROGENEOUS AIRWAYS DISEASE POPULATION\" class=\"state-synced\">EXHALED NITRIC OXIDE AND BLOOD EOSINOPHIL COUNT IN PREDICTING SPUTUM INFLAMMATORY TYPE IN A HETEROGENEOUS AIRWAYS DISEASE POPULATION</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1138301\" title=\"CHARACTERISATION OF EXACERBATIONS OF SEVERE EOSINOPHILIC ASTHMA ON MEPOLIZUMAB COMPARED TO PLACEBO\" class=\"state-synced\">CHARACTERISATION OF EXACERBATIONS OF SEVERE EOSINOPHILIC ASTHMA ON MEPOLIZUMAB COMPARED TO PLACEBO</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1138302\" title=\"CYTOF AND IN VITRO ANALYSIS OF THE ROLE OF IL-17A IN ASTHMA\" class=\"state-synced\">CYTOF AND IN VITRO ANALYSIS OF THE ROLE OF IL-17A IN ASTHMA</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1123048\" title=\"Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people\" class=\"state-synced\">Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">&lt;jats:sec&gt;&lt;jats:title&gt;Background&lt;/jats:title&gt;&lt;jats:p&gt;There is uncertainty about the associations of angiotensive enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied whether patients prescribed these drugs had altered risks of contracting severe COVID-19 disease and receiving associated intensive care unit (ICU) admission.&lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Methods&lt;/jats:title&gt;&lt;jats:p&gt;This was a prospective cohort study using routinely collected data from 1205 general practices in England with 8.28\u2009million participants aged 20\u201399 years. We used Cox proportional hazards models to derive adjusted HRs for exposure to ACE inhibitor and ARB drugs adjusted for sociodemographic factors, concurrent medications and geographical region. The primary outcomes were: (a) COVID-19 RT-PCR diagnosed disease and (b) COVID-19 disease resulting in ICU care.&lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Findings&lt;/jats:title&gt;&lt;jats:p&gt;Of 19\u2009486 patients who had COVID-19 disease, 1286 received ICU care. ACE inhibitors were associated with a significantly reduced risk of COVID-19 disease (adjusted HR 0.71, 95%\u2009CI 0.67 to 0.74) but no increased risk of ICU care (adjusted HR 0.89, 95%\u2009CI 0.75 to 1.06) after adjusting for a wide range of confounders. Adjusted HRs for ARBs were 0.63 (95% CI 0.59 to 0.67) for COVID-19 disease and 1.02 (95% CI 0.83 to 1.25) for ICU care.&lt;/jats:p&gt;&lt;jats:p&gt;There were significant interactions between ethnicity and ACE inhibitors and ARBs for COVID-19 disease. The risk of COVID-19 disease associated with ACE inhibitors was higher in Caribbean (adjusted HR 1.05, 95% CI 0.87 to 1.28) and Black African (adjusted HR 1.31, 95% CI 1.08 to 1.59) groups than the white group (adjusted HR 0.66, 95%\u2009CI 0.63 to 0.70). A higher risk of COVID-19 with ARBs was seen for Black African (adjusted HR 1.24, 95%\u2009CI 0.99 to 1.58) than the white (adjusted HR 0.56, 95%\u2009CI 0.52 to 0.62) group.&lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Interpretation&lt;/jats:title&gt;&lt;jats:p&gt;ACE inhibitors and ARBs are associated with reduced risks of COVID-19 disease after adjusting for a wide range of variables. Neither ACE inhibitors nor ARBs are associated with significantly increased risks of receiving ICU care. Variations between different ethnic groups raise the possibility of ethnic-specific effects of ACE inhibitors/ARBs on COVID-19 disease susceptibility and severity which deserves further study.&lt;/jats:p&gt;&lt;/jats:sec&gt;</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1080349\" title=\"MEPOLIZUMAB REDUCES EXACERBATIONS IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA IRRESPECTIVE OF BASELINE MAINTENANCE OCS USE: META-ANALYSIS FROM TWO PH3 TRIALS\" class=\"state-synced\">MEPOLIZUMAB REDUCES EXACERBATIONS IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA IRRESPECTIVE OF BASELINE MAINTENANCE OCS USE: META-ANALYSIS FROM TWO PH3 TRIALS</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1127832\" title=\"Using fractional exhaled nitric oxide to guide step-down treatment decisions in asthma: practical considerations\" class=\"state-synced\">Using fractional exhaled nitric oxide to guide step-down treatment decisions in asthma: practical considerations</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1136057\" title=\"Baseline characteristics from a phase 3, randomized controlled trial (COUGH-1) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough\" class=\"state-synced\">Baseline characteristics from a phase 3, randomized controlled trial (COUGH-1) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1136058\" title=\"Fractional exhaled nitric oxide levels and eosinophil counts after cessation of tezepelumab: Results from the PATHWAY phase 2b study\" class=\"state-synced\">Fractional exhaled nitric oxide levels and eosinophil counts after cessation of tezepelumab: Results from the PATHWAY phase 2b study</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1127798\" title=\"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.\" class=\"state-synced\">Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">BACKGROUND:Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatment for refractory chronic cough or unexplained chronic cough. METHODS:We did a 12-week, phase 2b, randomised, double-blind, placebo-controlled study in patients with refractory chronic cough or unexplained chronic cough aged 18-80 years who were recruited from 44 primarily outpatient pulmonologist or allergist sites in the UK and the USA. Eligible patients had refractory or unexplained chronic cough lasting 1 year or longer, no radiographic chest abnormality, and 40 mm or more on a 100-mm cough severity visual analogue scale at enrolment. Patients were randomly assigned to receive placebo or one of three doses (7\u00b75 mg, 20 mg, or 50 mg) of oral gefapixant twice daily, every day, for 84 days; visits to investigative sites were on days 1, 28, 42, 56, 70, 84, and 85. The randomisation schedule was computer generated using a permuted block algorithm by Advance Research Associates (Santa Clara, CA, USA). Patients and all personnel involved in the conduct and interpretation of the study were masked to treatment assignment. The primary endpoint was placebo-adjusted change from baseline in awake cough frequency after 12 weeks, assessed in the full analysis set, which is a subset of the intention-to-treat population. Adverse events were monitored and safety was evaluated in all patients receiving one or more doses of study drug. This trial is registered with ClinicalTrials.gov, NCT02612610. FINDINGS:Between Dec 21, 2015, and July 26, 2016, 253 patients were randomly assigned to placebo (n=63), gefapixant 7\u00b75 mg (n=64), gefapixant 20 mg (n=63), or gefapixant 50 mg (n=63) twice daily. The mean age of patients was 60\u00b72 (SD 9\u00b79) years and 193 (76%) were women. At 12 weeks, patients' geometric mean awake cough frequency was 18\u00b72 coughs per h (geometric SD 3\u00b71) with placebo, and 14\u00b75 coughs per h (3\u00b77) with 7\u00b75 mg, 12\u00b70 coughs per h (4\u00b72) with 20 mg, and 11\u00b73 coughs per h (2\u00b78) with 50 mg gefapixant. Estimated percentage change relative to placebo was -22\u00b70% (-41\u00b78 to 4\u00b76; p=0\u00b7097) with 7\u00b75 mg, -22\u00b72% (-42\u00b70 to 4\u00b73; p=0\u00b7093) with 20 mg, and -37\u00b70% (95% CI -53\u00b73 to -14\u00b79; p=0\u00b70027) with 50 mg gefapixant. Dysgeusia was the most common adverse event, occurring in three (5%) patients given placebo, six (10%) given 7\u00b75 mg gefapixant, 21 (33%) given 20 mg gefapixant, and 30 (48%) given 50 mg gefapixant. INTERPRETATION:Targeting purinergic receptor P2X3 with gefapixant at a dose of 50 mg twice daily significantly reduced cough frequency in patients with refractory chronic cough or unexplained chronic cough after 12 weeks of treatment compared with placebo. Further development of gefapixant is warranted for the treatment of chronic cough. FUNDING:Afferent Pharmaceuticals (acquired by Merck &amp; Co., Inc., Kenilworth, NJ, USA).</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1135168\" title=\"Response to mepolizumab treatment is sustained across 4-weekly dosing periods.\" class=\"state-synced\">Response to mepolizumab treatment is sustained across 4-weekly dosing periods.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Background:Mepolizumab (100 mg delivered s.c. every 4\u2005weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids, and improve asthma control and symptoms. However, data on the durability of the response to mepolizumab during dosing periods are limited. The aim of this study was to investigate the efficacy profile in patients with severe eosinophilic asthma over the 4-weekly dosing period for various fixed mepolizumab doses. Methods:This was a post hoc analysis of data from the phase IIb/III DREAM study. Patients \u226512\u2005years of age with severe eosinophilic asthma were randomised (1:1:1:1) to receive intravenous mepolizumab 75 mg (equivalent to 100 mg s.c.), 250 mg, 750 mg or placebo, plus standard of care, every 4\u2005weeks for 52\u2005weeks. The number of exacerbations and eDiary data (peak expiratory flow, rescue medication use and symptom scores) from two periods in each 4-weekly dosing interval (days 1-14 and 15-28) over the 52-week treatment period were analysed. Findings:eDiary data and the proportion of patients experiencing \u22651 exacerbation were similar during the first and second 2\u2005weeks of a dosing period across all mepolizumab doses. Interpretation:These results demonstrate that the response to mepolizumab is sustained over the 4-weekly dosing period with no differences across a 10-fold dose range and supports the use of the current mepolizumab dosing regimen in patients with severe eosinophilic asthma.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1130726\" title=\"BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED CONTROLLED TRIAL (COUGH-2) OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN REFRACTORY OR UNEXPLAINED CHRONIC COUGH\" class=\"state-synced\">BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED CONTROLLED TRIAL (COUGH-2) OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN REFRACTORY OR UNEXPLAINED CHRONIC COUGH</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1102089\" title=\"Targeted biologic therapy for asthma.\" class=\"state-synced\">Targeted biologic therapy for asthma.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">BACKGROUND:Asthma is a common and potentially serious condition affecting 300 million people worldwide. For many years, we have relied on a one-size-fits-all approach to its management, using corticosteroids and bronchodilators for all symptomatic patients. However, with more recent advances, it has become clear that asthma is a heterogeneous condition with multiple different underlying pathways. Understanding the different subtypes will be a key to giving us the ability to intervene in a targeted way to personalize care for patients with asthma. SOURCES OF DATA:Key published literature, guidelines and trials from clinicaltrials.gov. AREAS OF AGREEMENT:The most widely studied of these subtypes is T2 high eosinophilic asthma, for which there are an increasing number of biologic therapies available. T2 high asthma is associated with the cytokines interleukin (IL)-4, IL-5 and IL-13, for each of which biologics have been developed. AREAS OF CONTROVERSY:It is currently unclear which of the available biologics provides superior efficacy. It is also unclear how to select which biologic for which patient. GROWING POINTS:Head-to-head trials of the available T2 biologics will be important to determine superiority, and a suggested order for trialling biologics. Going further than this, we would like to see further analyses of available biologics to allow us to predict responders from non-responders in advance of administering therapy. AREAS TIMELY FOR DEVELOPING RESEARCH:Non-eosinophilic T2 low asthma is an area that is under-researched and for which there are few treatments available. It is likely that there are different subtypes in this category of asthma and unravelling what these are will be crucial to developing effective treatments.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1055727\" title=\"Point-of-care biomarkers in asthma management: Time to move forward.\" class=\"state-synced\">Point-of-care biomarkers in asthma management: Time to move forward.</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1114264\" title=\"Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design.\" class=\"state-synced\">Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Asthma is a chronic inflammatory airway disease. Increase in airway inflammation is hypothesised to contribute to worsening of asthma symptoms and deterioration in lung function, resulting in the use of reliever medication. Short-acting \u03b22-agonists only treat the symptoms, whereas an anti-inflammatory reliever is believed to treat both symptoms and the underlying inflammation, thereby arresting the progression to an exacerbation. As-needed budesonide/formoterol as an anti-inflammatory reliever reduces the risk of severe exacerbations. However, supporting mechanistic evidence has not yet been described, specifically the temporal dynamics of parameters including airway inflammation, over time and during asthma worsening. The STIFLE study aims to characterise daily variability in airway inflammation, symptoms, lung function and reliever use in people with asthma. This phase IV, open-label, parallel-group, multicentre, exploratory study will enrol 60-80 adult patients with asthma receiving low- or medium-dose inhaled corticosteroids/long-acting \u03b22-agonists (EudraCT identifier number 2018-003467-64). Participants will be randomised 1:1 to either as-needed budesonide/formoterol dry-powder inhaler or salbutamol reliever for 24\u2005weeks, in addition to their maintenance therapy. Daily data will be captured for fractional exhaled nitric oxide, spirometry, asthma symptoms and medication use using devices connected to a smartphone via the STIFLE application. STIFLE will thereby enable not only characterisation of the variability of airway inflammation and clinical outcomes in relation to asthma worsening, but also elucidate the effect of as-needed budesonide/formoterol on airway inflammation against a background of daily maintenance therapy.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1095341\" title=\"Step-up to high dose fluticasone furoate in combination with long-acting bronchodilator in inadequately controlled asthma: the CAPTAIN study\" class=\"state-synced\">Step-up to high dose fluticasone furoate in combination with long-acting bronchodilator in inadequately controlled asthma: the CAPTAIN study</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.ndmrb.ox.ac.uk/research/our-research/publications/1095342\" title=\"Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study\" class=\"state-synced\">Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n"
    ], 
    "more": "\n\n    \n        <a href=\"https://www.ndmrb.ox.ac.uk/@@search?b_start:int=80&amp;author=hannah-scott&amp;format=json&amp;amp=&amp;portal_type=publication&amp;random=1c9ae145-e23f-42b0-8869-e872c35554d4\" title=\"Load more\" class=\"btn btn-default load-more-button\">\n            Load More\n        </a>\n    \n\n", 
    "msg": ""
}